Merck (MRK) reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents. This significant upside was on account of a one-time charge incurred by the company in the year-ago quarter for a collaboration with Daiichi Sankyo.See the Zacks Earnings Calendar to stay ahead of market-making news.Revenues rose 7% year over year (9% excluding Fx) to $15.62 billion. Sales also beat the Zac ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

For the quarter ended December 2024, Merck (MRK) reported revenue of $15.62 billion, up 6.8% over the same period last year. EPS came in at $1.72, compared to $0.03 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $15.55 billion, representing a surprise of +0.45%. The company delivered an EPS surprise of +1.78%, with the consensus EPS estimate being $1.69.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they c ...

Key TakeawaysMerck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of estimates.Revenue and adjusted earnings, however, managed to top expectations.Sales of a few Merck drugs were hit by lower international demand and lower pricing in the U.S., the company said. Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue that topped expectations. Merck (MRK) reported $15.62 billion in revenue for the quarter, up 7% y ...

MRK and PFE have both been quiet on the charts latelyStocks are struggling for direction today, and one sector that represents this choppiness is blue-chip drugmakers. Merck & Co Inc (NYSE:MRK) and Pfizer Inc (NYSE:PFE) are both making outsized moves -- in opposite directions -- with the only common thread the ramped up option activity in response.MRK Eyes Worst Day in 17 YearsMerck, the maker of cancer drug Keytruda, reported fiscal year guidance below estimates. The whiff overshadows an earnings beat, and ...

Merck (MRK) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.69 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.78%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $1.50 per share when it actually produced earnings of $1.57, delivering a surprise of 4.67%.Over the last four quarters, the compan ...

On Tuesday, Merck & Co Inc MRK reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, sales increased 9%.Merck reported adjusted EPS of $1.72, up from $0.03 a year ago and beating the consensus of $1.62. Lower charges for business development transactions and operational strength primarily drove the increase."We delivered strong growth in 2024, reflecting demand for our innovative portfoli ...

MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a | | | | | 2024 | | | | | 2023 | | | % Change | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | Full | | | | | Full | | Full | | | | 1Q | 2Q | 3Q | 4Q | Year | 1Q | 2Q | 3Q | 4Q | Year | 4Q | Year | | Sales | | | | | | $ 15,775 $ 16,112 $ 16,657 $ 15,624 $ 64,168 $ 14,487 $ 15,035 $ 15,962 $ 14,630 $ 60,115 | | | | | | 7% | 7% ...

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations, as the company temporarily paused shipments of a key vaccine into China. The pharmaceutical giant anticipates 2025 sales of $64.1 billion to $65.6 billion, lower than the $67.31 billion that analysts surveyed by LSEG had expected. In a release, the company said that sales range reflects a decision to halt shipments of Gardasil into China beginning in February through and going through at least mid-2025. Ga ...

Merck (MRK) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate vaccine (PCV), Capvaxive, for the prevention of invasive pneumococcal disease (“IPD”) and pneumococcal pneumonia in individuals aged 18 years and above.The European Commission will now review the CHMP’s opinion and a final decision from the regulatory body is expected by the second quarter of 2025.The FDA approved Capvaxiv ...